Ocugen (OCGN) Other Non-Current Liabilities (2014 - 2026)
Ocugen posted quarterly Other Non-Current Liabilities of $3.0 million for Q1 2026, up 415.01% year-on-year from $573000.0 in Q1 2025, and up 84.09% on a QoQ basis from $1.6 million in Q4 2025.
Ocugen (OCGN) has 12 years of Other Non-Current Liabilities data on file, last reported at $3.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 415.01% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (up 415.01% YoY), and the FY2025 full-year result was $1.6 million, up 184.22% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $3.0 million, up from $1.6 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.0 million in Q1 2026 and bottomed at $244000.0 in Q4 2022.
- The 5-year median for Other Non-Current Liabilities is $549500.0 (2024), against an average of $823857.1.
- The widest annual swing landed in 2025, when Other Non-Current Liabilities climbed 6.9%; it then soared 415.01% in 2026.
- A 5-year view of Other Non-Current Liabilities shows it stood at $244000.0 in 2022, then soared by 115.98% to $527000.0 in 2023, then increased by 7.02% to $564000.0 in 2024, then soared by 184.22% to $1.6 million in 2025, then surged by 84.09% to $3.0 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $3.0 million (Q1 2026), $1.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.95 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | 583,000.00 |
| Mar 31, 2025 | 573,000.00 |
| Dec 31, 2024 | 564,000.00 |
| Sep 30, 2024 | 554,000.00 |
| Jun 30, 2024 | 545,000.00 |
| Mar 31, 2024 | 536,000.00 |
| Dec 31, 2023 | 527,000.00 |
| Sep 30, 2023 | 497,000.00 |
| Jun 30, 2023 | 455,000.00 |
| Mar 31, 2023 | 309,000.00 |
| Dec 31, 2022 | 244,000.00 |
| Mar 31, 2020 | 3,940.00 |
| Dec 31, 2019 | 9,755.00 |
| Jun 30, 2019 | 64,347.00 |
| Mar 31, 2019 | 10,000.00 |
| Dec 31, 2018 | 37,459.00 |
| Sep 30, 2018 | 1.09 Mn |
| Jun 30, 2018 | 714,041.00 |
| Mar 31, 2018 | 23.43 Mn |
| Dec 31, 2017 | 14.68 Mn |
| Sep 30, 2017 | 13.87 Mn |
| Jun 30, 2017 | 555,000.00 |
| Mar 31, 2017 | 583,000.00 |
| Dec 31, 2016 | 610,000.00 |
| Sep 30, 2016 | 712,000.00 |
| Jun 30, 2016 | 814,000.00 |
| Mar 31, 2016 | 915,000.00 |
| Dec 31, 2015 | 1.02 Mn |
| Sep 30, 2015 | 1.15 Mn |
| Jun 30, 2015 | 1.22 Mn |
| Mar 31, 2015 | 1.21 Mn |
| Dec 31, 2014 | 1.32 Mn |